The Limited Times

Now you can see non-English news...

It will cost less than 4 dollars and will be available early next year: this will be the vaccine that will be produced in Argentina

2020-08-14T08:25:16.975Z


February or March is the probable date for the possible vaccine against covid-19 that the University of Oxford and AstraZeneca will produce in Argentina for Latin America, Esteban Corle told CNN Radio ...


When would the vaccine from Mexico and Argentina be certified? 4:31

(CNN Spanish) - "We plan to get the first batches for February or March." That is the probable date for the possible vaccine against covid-19 that the University of Oxford and the AstraZeneca laboratory will produce in Argentina for Latin America.

This was explained this Thursday to CNN Radio Esteban Corley, director of mAbxience, the Argentine biotechnology company that will produce the active principle of this vaccine. "Once produced in the country, it has to go to Mexico, be formulated and packaged in syringes," he added.

"Some 250 million doses will be available in a first stage," which will be distributed throughout the region, except Brazil, which has other agreements, Corley added.

Key facts about the Oxford vaccine in Latin America 0:58

The Slim Foundation, owned by the Mexican telecommunications magnate Carlos Slim, also participates in the project and thanks to its financing the vaccine will have "more reasonable prices", between 3 and 4 dollars, according to the president of Argentina Alberto Fernández. "A differential price, very different from what other manufacturers say," said the Argentine Minister of Health, Ginés González García, who added: "It gives us accessibility especially in a country where there are economic difficulties."

Beyond the fact that the announcements were made by the governments of Argentina and Mexico, both development and financing are done by private parties. Also the risk if the vaccine finally does not work.

  • What we know about the vaccine from AstraZeneca and the University of Oxford that Mexico and Argentina will produce

"In order not to wait, AstraZeneca asked the companies to work at risk: that is, if the vaccine is approved, it will be sold, but if it is not, what was done will be thrown away", explained Hugo Sigman, owner of the Group Insud, to which mAbxience belongs, in an interview on Argentina's Radio Miter.

The vaccine has already passed the first two phases and is now in a third, where its effectiveness is tested and it contemplates inoculation in thousands of people in several countries to demonstrate its effectiveness against the Sars Cov-2 virus.

"Immunity with one dose, according to an international study, is detected in 91% of people and that is very high, but with a second dose, in the second month, 100% was achieved," explained the Minister of Health of Argentina .

This is the inside of the laboratory that will create Oxford vaccine 2:50

By producing it in the country, Latin America will have "the vaccine at the same time as the central countries," added Sigman, in line with Fernández's sayings, who on Wednesday had said that, thanks to this agreement, Argentina will access "between six and twelve months before the vaccine »

The government maintained that the first to receive the vaccine will be those who make up the population at risk: people over 60 with risk factors, health personnel and security forces.

Beyond this initial production of 250 million doses, mAbxience clarified that "in case more is required, the production capacity will be assembled so that it will be able to meet."

Although the president stressed that the Oxford vaccine "comes ahead in the clinical phase" among those that are developed in the world against the coronavirus, the Argentine government clarified that this "is not the only negotiation or the only alternative."

What are the political ends behind vaccines? 9:51

The Minister of Health said that Argentina continues to "talk with other providers" to ensure "the most effective vaccine." For this reason, it is also negotiating other studies, such as that of the pharmaceutical company CanSino and the Chinese military research unit, and BioNTech and Pfizer, which is conducting clinical trials in the country.

"This is a great relief for the future, it is not a solution for the present, in the present we continue to have the same problems that we are seeing," said Fernández during the presentation of the agreement, referring to the growth in the number of infected and dead by covid-19 in the country.

Coronavirus vaccine

Source: cnnespanol

All news articles on 2020-08-14

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.